Incyte Corp. closed 14.97% short of its 52-week high of $83.95, which the company reached on November 8th.

“Partnering with Genesis Therapeutics presents a unique opportunity to leverage their AI technologies to accelerate the ...

Incyte and Genesis have entered a strategic partnership for the research, discovery and development of new small-molecule ...

Incyte (INCY) and Genesis Therapeutics announced that the companies have entered into a strategic collaboration focused on the research, ...

Incyte and Genesis Therapeutics have agreed to discover and optimize at least two initial small molecule compounds through Genesis’s AI platform, Genesis Exploration of Molecular Space (GEMS).

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March: ...

Incyte and Genesis will leverage Genesis’ GEMS artificial intelligence (AI) platform to unlock the discovery of breakthrough small molecule therapeutics against Incyte-selected targets Incyte ...

Incyte is granted exclusive rights for potential clinical development and commercialization of collaboration products. “AI has the potential to redefine how we discover small molecule medicines ...

WILMINGTON, Del., February 18, 2025--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March: Cowen 45 th Annual ...

Incyte Corporation, a biopharmaceutical company focused on developing proprietary therapeutics, finds itself at a critical juncture as it navigates the challenges of an impending patent cliff ...